Iksha Herr of Microsoft previews her talk on leveraging data and artificial intelligence (AI) in health care, which will be a high point of this year's Patient-Centered Oncology Care® (PCOC) conference.
Iksha Herr is the managing director of data and artificial intelligence (AI) at Microsoft's Healthcare & Life Sciences department. Herr will be the keynote speaker for the 10th anniversary of Patient-Centered Oncology Care® (PCOC) conference.
Transcript
Your keynote address starts with the idea that a true patient-centered health care continuum is still a work in progress. Why, in your view, is health care still so disconnected?
I really think there is recognition that it is a continuum. So, each of these areas, drug development, providing health services to patients, and then the payer part, which is paying for the cost of the services and drug development, are connected, but I think there is a lack of coordination and synchronization and an understanding that each of these parts has a very significant role to play for the other parts. I think that's where the lack of urgency and addressing those parts is the reason for this.
A second major idea of your talk is that both people and patients are needed to leverage the full potential of data and AI. Can you elaborate on your distinction between people and patients?
So, because I am so focused on data and AI, and how data and AI can play a role in the health care continuum, I see the use of good quality data as a very important piece of the puzzle to solve all the health care issues that we have. And where good data comes from is not just patients, but also people because people can participate by providing data by using their voice to shape policy around data and AI, and also participating in informing care and being a part of this data and AI ecosystem to solve the health care issues that we have.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More